Evidence map›Paper›PMID 41379161›Full record

ArticleJournal of molecular neuroscience : MN2025

The Isoflavone Formononetin Suppresses Hallmarks of Glioblastoma Progression and Activates a Compensatory Antioxidant Pathway.

Fatemeh Dinarvand, Mehdi Salehi, Seyyed Amirhossein Latifi, Hadi Karami

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fatemeh DinarvandMolecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.
Mehdi SalehiTraditional and Complementary Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.
Seyyed Amirhossein LatifiTraditional and Complementary Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.
Hadi KaramiMolecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran. hadimolmed@gmail.com.ORCID http://orcid.org/0000-0002-8824-8160

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the anti-glioblastoma potential of the natural isoflavone formononetin, focusing on its impact on cell survival, proliferation, migration, mediated through a potential mechanism involving oxidative stress modulation. T98G glioblastoma cells were treated with formononetin (IC

Indexed as

Antineoplastic AgentsAntioxidantsGlioblastomaIsoflavonesApoptosisCell Line, TumorCell MovementCell ProliferationCyclin D1Glutathione PeroxidaseHumansMatrix Metalloproteinase 9Superoxide DismutaseSurvivinAntineoplastic AgentsAntioxidantsCyclin D1formononetinGlutathione PeroxidaseIsoflavonesMatrix Metalloproteinase 9Superoxide DismutaseSurvivinAntioxidantApoptosisFormononetinGlioblastomaOxidative stress

Identifiers

PMID41379161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.